Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
22.23
-1.77 (-7.37%)
At close: Aug 1, 2025, 4:00 PM
22.24
+0.01 (0.04%)
After-hours: Aug 1, 2025, 4:46 PM EDT
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer.
The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer.
Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States | |
| Phone | 972 499 3350 |
| Website | instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C2008 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman and Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer and Chief Business Officer |
| Dr. James Freedman M.D., Ph.D. | Chief Medical Officer |
| Dr. Qiying Lu M.D. | Chief Medical Officer and Senior Vice President of China |
| Dr. Rupal Bhatt M.D., Ph.D. | Senior Vice President of Science and Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 27, 2025 | 8-K | Current Report |
| May 22, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 2, 2025 | DEFR14A | Filing |
| Apr 14, 2025 | ARS | Filing |